New Anti-Obesity Drug Retatrutida Achieves Record 30% Weight Loss in Clinical Trials

A new anti-obesity drug, retatrutida, has shown unprecedented results in clinical trials, leading to an average weight loss of 30.3% (38.5 kg) over two years in individuals with morbid obesity, marking a significant breakthrough in GLP-1 related medications.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

el-mundoSpanish15d ago

Un nuevo fármaco antiobesidad rompe récords al lograr una pérdida de peso del 30% a los dos años

Los resultados de retatrutida, la tercera generación de los medicamentos GLP, muestran reducciones medias de 38,5 kg, equivalentes al 30,3% del peso corporal, en personas con obesidad mórbida Leer

Read full article →

PERSPECTA

PERSPECTA

New Anti-Obesity Drug Retatrutida Achieves Record 30% Weight Loss in Clinical Trials

Sources

Un nuevo fármaco antiobesidad rompe récords al lograr una pérdida de peso del 30% a los dos años

Related Stories

'Astronauts back on Earth': Artemis II crew splashes down after record-breaking moon flyby – video

Rökkvi Hljómur Graduates from Agricultural University of Iceland

Over 70 New Species Discovered on Remote Angolan Plateau

Viper Causes Emergency Call After Entering Finnish Home

PERSPECTA